10-Q: ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Clinical Trial Update

ALX Oncology's second quarter 2024 results show increased R&D spending and a net loss, alongside positive clinical trial updates for their lead product candidate, evorpacept.

Summary

• ALX Oncology reported a net loss of $39.4 million for the three months ended June 30, 2024, compared to a net loss of $34.2 million for the same period in 2023.
• The company's research and development expenses increased to $34.7 million for the quarter, up from $29.5 million in the prior year.
• General and administrative expenses decreased slightly to $6.9 million from $7.3 million year-over-year.
• The company's cash, cash equivalents, and investments totaled $186.2 million as of June 30, 2024.
• ALX Oncology believes its current capital resources will fund operations into the first quarter of 2026.
• The company highlighted positive topline data from the ASPEN-06 Phase 2 clinical trial, showing a 40.3% overall response rate for the Evo-TRP treatment arm compared to 26.6% for the TRP control arm.
• The company also reported an unconfirmed overall response rate of 61% in the ASPEN-07 trial for evorpacept plus enfortumab vedotin-ejfv in urothelial cancer.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical trial results and ongoing financial losses. The positive clinical data, especially from the ASPEN-06 and ASPEN-07 trials, is encouraging, but the company's continued losses and need for additional capital temper the overall sentiment. The company's ability to execute its business plan and secure regulatory approvals will be key to future success.

Positives

• The ASPEN-06 trial demonstrated a promising and durable response with a well-tolerated safety profile for evorpacept in a randomized trial.
• The ASPEN-07 trial showed a high unconfirmed overall response rate of 61% with evorpacept plus enfortumab vedotin-ejfv in urothelial cancer.
• The company has multiple ongoing collaborations and investigator-sponsored trials, expanding the potential applications of evorpacept.
• The company has sufficient capital to fund operations into the first quarter of 2026.
• The company has a diverse pipeline with multiple clinical trials and preclinical programs.

Negatives

• The company continues to incur significant net losses, with a $39.4 million loss for the quarter.
• Research and development expenses increased significantly, indicating high spending on clinical trials and preclinical programs.
• The company is dependent on third-party manufacturers for clinical supplies, which could lead to delays or supply issues.
• The company has a limited operating history and no products approved for commercial sale.

Risks

• The company is substantially dependent on the success of evorpacept, which is still in clinical development.
• Clinical trials are expensive, time-consuming, and may not demonstrate adequate safety and efficacy.
• The regulatory approval processes are lengthy and unpredictable, which could delay or prevent product commercialization.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The company relies on third-party manufacturers for clinical supplies, which could lead to delays or supply issues.
• The company's debt and compliance with the terms of its loan agreement could restrict its ability to operate its business.
• The company's stock price may be volatile, and investors could lose all or part of their investment.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms or at all.

Future Outlook

The company believes its existing capital resources will be sufficient to fund its projected operating requirements for at least the next twelve months and into the first quarter of 2026. The company expects to continue to incur significant expenses and increasing operating losses for the foreseeable future as it advances its clinical trials and preclinical programs.

Management Comments

• Management expects to incur additional losses in the future to conduct product candidate research and development and to conduct pre-commercialization activities.
• Management recognizes the need to raise additional capital to fully implement its business plan.
• The company believes that the existing capital resources will be sufficient to fund the projected operating requirements for at least the next twelve months.

Industry Context

The announcement reflects the ongoing trend in the biotechnology industry of companies focusing on immuno-oncology therapies. The positive clinical trial results for evorpacept, particularly in combination with other therapies, highlight the potential of this approach in cancer treatment. The company is competing with other companies developing CD47-targeting therapies, as well as other immuno-oncology approaches.

Comparison to Industry Standards

• The reported overall response rate of 40.3% in the ASPEN-06 trial for the Evo-TRP arm is competitive with other targeted therapies in second-line gastric/GEJ cancer.
• The 54.8% ORR in patients with fresh HER2-positive biopsies in the ASPEN-06 trial suggests a strong correlation between HER2 expression and evorpacept efficacy, which is a positive signal compared to other trials in this space.
• The unconfirmed ORR of 61% in the ASPEN-07 trial for evorpacept plus enfortumab vedotin-ejfv in urothelial cancer is promising, especially when compared to the benchmark of 41% for enfortumab vedotin-ejfv alone.
• The 94% ORR and 83% CRR in indolent R/R B-NHL patients in the IST of evorpacept with rituximab and lenalidomide are very high and suggest a strong potential for this combination therapy.
• Companies like Gilead Sciences (through its acquisition of Forty Seven) and Pfizer (through its acquisition of Trillium Therapeutics) are also developing CD47-targeting therapies, making the competitive landscape intense.
• The company's approach of combining evorpacept with other anti-cancer agents, such as antibodies and checkpoint inhibitors, is consistent with current trends in immuno-oncology.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• The company has several related-party agreements with Tallac Therapeutics, Inc., and ScalmiBio, Inc.
• The Tallac Services Agreement terminated on July 1, 2024.
• The company made a $1.0 million milestone payment to the stockholders of ScalmiBio as a result of selecting a development candidate.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may benefit from the company's growth and development.
• Patients may benefit from the development of new cancer therapies.
• Suppliers and creditors may benefit from the company's ongoing operations.
• The company's success will depend on its ability to obtain regulatory approvals and commercialize its product candidates.

Next Steps

• The company will continue to advance evorpacept through multiple clinical trials in various indications.
• The company will pursue regulatory approval of evorpacept in solid tumors and hematological malignancies.
• The company will continue its discovery and preclinical and clinical development efforts, including collaborations with Sanofi, Tallac, Jazz, and Quantum Leap and its acquisition of ScalmiBio.
• The company will seek to obtain and maintain patent, trade secret, and other intellectual property protection and regulatory exclusivity for its product candidates.
• The company will continue to manufacture supplies for its preclinical studies and clinical trials.
• The company will continue to add operational, financial, and management information systems to support ongoing operations as a public company.

Key Dates

Keywords

evorpacept, CD47, immuno-oncology, clinical trials, cancer therapy, ASPEN-06, ASPEN-07, HER2-positive, urothelial cancer, non-Hodgkin lymphoma, R&D, biotechnology